清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

[Risk factors for visual field loss progression in patients with primary open-angle glaucoma in Wenzhou area].

医学 青光眼 眼科 开角型青光眼 眼压 曼惠特尼U检验 视野 比例危险模型 前瞻性队列研究 临床终点 相对风险 统计显著性 视野丧失 外科 内科学 置信区间 随机对照试验
作者
Kun Zhou,Xiao Shang,Xiaoyan Wang,Xuejun Wang,Cheng Hh,Hu Hs,Huang Qj,X-F Pan,Xiaoyu Xu,Liang Yb
出处
期刊:PubMed 卷期号:55 (10): 777-784 被引量:7
标识
DOI:10.3760/cma.j.issn.0412-4081.2019.10.009
摘要

Objective: To evaluate risk factors for visual field (VF) loss progression in primary open-angle glaucoma patients. Methods: A prospective nested case-control study. Patients were collected from the Wenzhou glaucoma progression study in the Eye Hospital of Wenzhou Medical University during March 2014 and April 2018. In this study, the eyes were divided into a progression group and a non-progression group using the glaucoma progression analysis methods to analyze the risk factors for glaucomatous VF loss progression. Axial length (AL) and central corneal thickness (CCT) were measured using the Lenstar LS900. The baseline, fluctuation (standard deviation), mean, maximum, minimum and range of intraocular pressure (IOP) during the follow-up period were determined based on IOP measured at each follow-up. The IOP measurements were included from the baseline to the last visit (for the non-progression group), or to the visit at which VF loss progression was determined (for the progression group). The independent sample t-test, Mann-Whitney U inspection and Cox proportional hazards models were used for statistical analysis. Results: A total of 140 patients (140 eyes) were enrolled, including 67 males and 73 females. There were 19.3% of the eyes (27 of 140 eyes) showing VF loss progression. The median time to the endpoint for progression was 24.0 (16.0, 40.0) months. The AL in the progression group and non-progression group were 23.58 (23.05, 24.24) mm and 23.91 (23.10, 24.91) mm (P=0.111). The CCT in the two groups were 531.0 (512.0, 565.0) μm and 535.0 (518.5, 552.0) μm, respectively (P=0.897). The baseline age in the progression group and non-progression group was 71.0 (68.0, 74.0) years and 68.0 (58.0, 72.0) years, respectively (Z=-2.872, P=0.004). The slope of visual field index in the two groups was -3.50 (-7.10, -1.80)%/year and 0.40 (-0.60, 1.40)%/year, respectively (Z=-6.823, P<0.01). The mean IOP during the follow-up was (16.2±2.7) mmHg (1 mmHg=0.133 kPa) in the progression group and (15.1±2.4) mmHg in the non-progression group (t=-2.215, P=0.028). The IOP fluctuation in the progression group and non-progression group was (2.6±1.3) mmHg and (2.0±0.7) mmHg, respectively (t=-2.175, P=0.038). In the multivariate model, older baseline age (HR=1.080; 95%CI:1.019-1.143), higher baseline IOP (HR=1.120; 95%CI:1.016-1.236), higher mean IOP (HR=1.145; 95%CI:1.001-1.309) and higher IOP fluctuation (HR=1.750; 95%CI:1.193-2.566) were all significantly predictive risk factors for glaucomatous VF loss progression. Longer AL (HR=0.725; 95%CI:0.532-0.988) was a protective factor against VF loss progression. However, CCT was found to be not associated with VF loss progression. Conclusion: Baseline age, baseline IOP, mean IOP, IOP fluctuation and shorter AL are found to be risk factors for glaucomatous VF loss progression among eyes with primary open-angle glaucoma in Wenzhou. (Chin J Ophthalmol, 2019, 55: 777-784).目的: 探讨温州地区原发性开角型青光眼(POAG)患者视野缺损进展的危险因素。 方法: 前瞻性巢式病例对照研究。收集2014年3月至2018年4月于温州医科大学附属眼视光医院进行的温州青光眼进展研究中确诊的POAG患者,随访中观察患者视野缺损进展情况,采用青光眼进展分析法将患眼分为视野缺损进展组和视野缺损非进展组。采用Lenstar眼科光学生物仪测量眼轴长度和中央角膜厚度(CCT);根据每次随访时测得的眼压确定基线眼压及随访期间的眼压波动值(标准差)、平均眼压、最高眼压、最低眼压、眼压范围,视野缺损非进展组眼压数据截至最近一次随访,视野缺损进展组眼压数据截至进展当次随访。采用独立样本t检验、Mann-Whitney U检验及Cox比例风险模型进行统计学分析。 结果: 共纳入分析140例(140只眼)患者,其中男性67例,女性73例。19.3%(27/140)的患眼出现视野缺损进展,进展的中位时间为24.0(16.0,40.0)个月。视野缺损进展组、视野缺损非进展组眼轴长度分别为23.58(23.05,24.24)、23.91(23.10,24.91)mm(P=0.111),CCT分别为531.0(512.0,565.0)、535.0(518.5,552.0)μm(P=0.897),差异均无统计学意义;两组基线年龄分别为71.0(68.0,74.0)、68.0(58.0,72.0)岁(Z=-2.872,P=0.004),视野指数改变速率分别为-3.50(-7.10,-1.80)、0.40(-0.60,1.40)%/年(Z=-6.823,P<0.01),随访平均眼压分别为(16.2±2.7)、(15.1±2.4)mmHg(1 mmHg=0.133 kPa)(t=-2.215,P=0.028),随访眼压波动值分别为(2.6±1.3)、(2.0±0.7)mmHg(t=-2.175,P=0.038),差异均有统计学意义。多因素Cox比例风险模型显示基线年龄(HR=1.080;95%CI:1.019~1.143)、基线眼压(HR=1.120;95%CI:1.016~1.236)、随访平均眼压(HR=1.145;95%CI:1.001~1.309)及眼压波动值(HR=1.750;95%CI:1.193~2.566)越大,视野缺损进展风险越大;眼轴长度(HR=0.725;95%CI:0.532~0.988)越大,视野缺损进展风险越小。未发现CCT与视野缺损进展的关系(HR=1.000;95%CI:0.988~1.011)。 结论: 温州地区POAG人群中基线年龄大、基线眼压高、随访平均眼压高及眼压波动值大、眼轴长度短为POAG视野缺损进展的危险因素。(中华眼科杂志,2019,55:777-784).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
10秒前
智慧门完成签到 ,获得积分10
10秒前
12秒前
潇洒的凝梦完成签到,获得积分20
14秒前
yoozii发布了新的文献求助10
18秒前
忧郁凌波发布了新的文献求助10
19秒前
忧郁凌波完成签到,获得积分10
28秒前
29秒前
kevin_kong完成签到,获得积分10
32秒前
Wucaihong完成签到 ,获得积分10
33秒前
一天完成签到 ,获得积分10
41秒前
48秒前
sobergod完成签到 ,获得积分10
57秒前
sevenhill完成签到 ,获得积分0
1分钟前
缓慢的初兰完成签到,获得积分10
1分钟前
1分钟前
cdercder应助spinon采纳,获得10
1分钟前
YZY完成签到 ,获得积分10
1分钟前
1分钟前
激动的似狮完成签到,获得积分0
1分钟前
1分钟前
简单完成签到 ,获得积分10
1分钟前
spinon完成签到,获得积分10
1分钟前
FF发布了新的文献求助10
2分钟前
2分钟前
会飞的柯基完成签到 ,获得积分10
2分钟前
2分钟前
白菜炖大鹅完成签到,获得积分10
2分钟前
2分钟前
心灵美的不斜完成签到 ,获得积分10
2分钟前
ZYD完成签到 ,获得积分10
2分钟前
qin完成签到 ,获得积分10
2分钟前
汉堡包应助Yiphy采纳,获得50
3分钟前
科研通AI2S应助科研通管家采纳,获得10
3分钟前
3分钟前
Xulyun完成签到 ,获得积分10
3分钟前
蔡勇强完成签到 ,获得积分10
3分钟前
Lillianzhu1完成签到,获得积分10
3分钟前
zxx完成签到 ,获得积分10
3分钟前
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Prompt Engineering for Clinicians: Harnessing AI in Everyday Medical Practice 600
REAL-WORLD EFFICACY AND GENOMIC LANDSCAPE OF POLATUZUMA VEDOTIN-BASED FIRST-LINE THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA: A FOCUS ON TP53 MUTATIONS AND TREATMENT RESPONSE 500
Handbook of Luminescence Dating 500
Safety Pharmacology 500
《KNN基无铅压电陶瓷电学性能优化与物理机理研究》 500
Treatment of refractory idiopathic overactive bladder with incobotulinumtoxinA and vibe delivery system (XAVIER): pilot study 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 计算机科学 化学工程 生物化学 物理 内科学 复合材料 催化作用 光电子学 物理化学 电极 细胞生物学 基因 遗传学
热门帖子
关注 科研通微信公众号,转发送积分 6949329
求助须知:如何正确求助?哪些是违规求助? 8633959
关于积分的说明 18308487
捐赠科研通 6389474
什么是DOI,文献DOI怎么找? 3081217
关于科研通互助平台的介绍 2125066
邀请新用户注册赠送积分活动 2058133